What’s the current market cap for iRhythm stock?

iRhythm (IRTC) has a market cap of $3.8B as of May 25, 2026.

What is the P/E ratio for iRhythm stock?

The price to earnings (P/E) ratio for iRhythm (IRTC) stock is 0 as of May 25, 2026.

Does iRhythm stock pay dividends?

No, iRhythm (IRTC) stock does not pay dividends to its shareholders as of May 25, 2026.

When is the next iRhythm dividend payment date?

iRhythm (IRTC) stock does not pay dividends to its shareholders.

What is the beta indicator for iRhythm?

iRhythm (IRTC) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy iRhythm stock | $IRTC Share Price

13:30

15:10

16:45

18:25

20:00

About iRhythm

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Ticker

$IRTC

Sector

Health

Primary listing

NASDAQ

Employees

2,400

Headquarters

San Francisco, United States

Website

www.irhythmtech.com

iRhythm Metrics

BasicAdvanced

$3.8bn

-$0.86

1.18

What the Analysts think about iRhythm

Analyst ratings (Buy, Hold, Sell) for iRhythm stock.

Bulls say / Bears say

iRhythm posted Q1 2026 revenue of $199.4 million, up 25.7% year-over-year, fueled by strong volume growth in cardiology, primary care, new partnerships, and international markets (SEC).

Management raised its full-year 2026 revenue outlook to $875 million–$885 million (17%–18% growth) and its adjusted EBITDA margin to 12.0%–13.0%, showing confidence in strong demand and operational efficiency (SEC).

The company achieved its first full year of positive free cash flow in 2025 with a 9.2% adjusted EBITDA margin, and ended Q1 2026 with $549.6 million in unrestricted cash and marketable securities, providing solid liquidity for continued investment (SEC; SEC).

iRhythm reported a net loss of $13.9 million in Q1 2026, showing the company is still operating at a loss despite increased revenue (SEC).

The company ended 2025 with a full-year GAAP net loss of $44.6 million, pointing to ongoing annual losses even though revenue was up 26.2% year-over-year (SEC).

Future growth depends on regulatory approval of the next-generation Zio MCT device—since the 510(k) submission was only made in Q3 2025 and commercial launch isn’t expected before the first half of 2027, this exposes future revenue to approval risk (SEC).

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.

iRhythm Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

iRhythm Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRTC

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

iRhythm posted Q1 2026 revenue of $199.4 million, up 25.7% year-over-year, fueled by strong volume growth in cardiology, primary care, new partnerships, and international markets (SEC).

iRhythm reported a net loss of $13.9 million in Q1 2026, showing the company is still operating at a loss despite increased revenue (SEC).

The company ended 2025 with a full-year GAAP net loss of $44.6 million, pointing to ongoing annual losses even though revenue was up 26.2% year-over-year (SEC).

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.